MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1681/asn.2019050546

Медицинская библиотека · Journal of the American Society of Nephrology : JASN · 2020

Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.

Chin Ho Jun, Chae Dong-Wan, Kim Yong Chul, An Won Suk, Ihm ChunGyoo, Jin Dong-Chan, Kim Sung Gyun, Kim Yong-Lim, Kim Yong-Soo, Kim Yoon-Goo, Koo Ho Seok, Lee Jung Eun, Lee Kang Wook, Oh Jieun, Park Jung Hwan, Jiang Hongsi, Lee Hyuncheol, Lee Sang Koo

Сравнительное исследованиеСтатьяМногоцентровое исследованиеРандомизированное исследованиеEquivalence TrialПеревод в очереди

Аннотация

BACKGROUND

Tacrolimus is used as a steroid-sparing immunosuppressant in adults with minimal change nephrotic syndrome. However, combined treatment with tacrolimus and low-dose steroid has not been compared with high-dose steroid for induction of clinical remission in a large-scale randomized study.

METHODS

In this 24-week open-label noninferiority study, we randomized 144 adults with minimal change nephrotic syndrome to receive 0.05 mg/kg twice-daily tacrolimus plus once-daily 0.5 mg/kg prednisolone, or once-daily 1 mg/kg prednisolone alone, for up to 8 weeks or until achieving complete remission. Two weeks after complete remission, we tapered the steroid to a maintenance dose of 5-7.5 mg/d in both groups until 24 weeks after study drug initiation. The primary end point was complete remission within 8 weeks (urine protein: creatinine ratio <0.2 g/g). Secondary end points included time until remission and relapse rates (proteinuria and urine protein: creatinine ratio >3.0 g/g) after complete remission to within 24 weeks of study drug initiation.

RESULTS

Complete remission within 8 weeks occurred in 53 of 67 patients (79.1%) receiving tacrolimus and low-dose steroid and 53 of 69 patients (76.8%) receiving high-dose steroid; this difference demonstrated noninferiority, with an upper confidence limit below the predefined threshold (20%) in both intent-to-treat (11.6%) and per-protocol (17.0%) analyses. Groups did not significantly differ in time until remission. Significantly fewer patients relapsed on maintenance tacrolimus (3-8 ng/ml) plus tapered steroid versus tapered steroid alone (5.7% versus 22.6%, respectively; P=0.01). There were no clinically relevant safety differences.

CONCLUSIONS

Combined tacrolimus and low-dose steroid was noninferior to high-dose steroid for complete remission induction in adults with minimal change nephrotic syndrome. Relapse rates were significantly lower with maintenance tacrolimus and steroid compared with steroid alone. No clinically-relevant differences in safety findings were observed.

Для цитирования: Chin Ho Jun, Chae Dong-Wan, Kim Yong Chul, An Won Suk, Ihm ChunGyoo, Jin Dong-Chan, Kim Sung Gyun, Kim Yong-Lim, Kim Yong-Soo, Kim Yoon-Goo, Koo Ho Seok, Lee Jung Eun, Lee Kang Wook, Oh Jieun, Park Jung Hwan, Jiang Hongsi, Lee Hyuncheol, Lee Sang Koo. Comparison of the Efficacy and Safety of Tacrolimus and Low-Dose Corticosteroid with High-Dose Corticosteroid for Minimal Change Nephrotic Syndrome in Adults.. Journal of the American Society of Nephrology : JASN. 2020. DOI: 10.1681/asn.2019050546.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.